Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (104)	10/2/2003 7:30:17 AM
From: Thomas	Read Replies (2) \| Respond to of 671

Tuck, SemiBull et al, Anyone have a view on the Sirna presentation at the UBS conference? The slides and charts showing stability and in vitro response looked impressive, but I am not skilled enough to know whether that data is meaningful or has relevance to expected in vivo efficacy. Also found it interesting to listen to the Alnylam presentation (albeit without the slides). The Alnylam presentation placed strong emphasis on their IP portfolio, walking through the key patent groups in detail. Also (predictably), they emphasized the Merck partnership. What a huge coup for Alnylam. Talked a lot about the huge troves of validated targets that big pharma has on the shelves. The discussion of delivery challenges was interesting, including potential use of "entrodigal" [sic] devices and coated stents. For their in vivo trials in DBOB mice (Diabetes/Obesity), they used a "hydrodynamic" [sic] injection method, which they said is not ready for human use, but was good for the trial. The stabilized siRNA's lasted 3 days and reduced the [serum count-don't remember exactly what they were measuring, sorry] by 50% from 400ml to 200ml compared to the controls. Thanks in advance. Cheers, Thomas